Log in
Enquire now
Soligenix

Soligenix

Soligenix is a Princeton, New Jersey-based developer of biodefense vaccines and therapeutics for the side-effects of cancer treatment and gastrointestinal diseases.

OverviewStructured DataIssuesContributors

Contents

soligenix.com
Is a
Company
Company
Organization
Organization

Company attributes

Industry
Technology
Technology
Biopharmaceutical
Biopharmaceutical
0
Engineering
Engineering
0
Biosecurity
Biosecurity
Pharmaceutical industry
Pharmaceutical industry
Therapeutics
Therapeutics
...
Location
Princeton, New Jersey
Princeton, New Jersey
0
B2X
B2B
B2B
0
CEO
‌
Christopher J. Schaber
0
Founder
‌
Christopher J. Schaber
AngelList URL
angel.co/soligenix
Pitchbook URL
pitchbook.com/profiles.../41938-48
Legal Name
Soligenix, Inc0
Date Incorporated
1987
Number of Employees (Ranges)
11 – 50
Email Address
info@soligenix.com
Phone Number
+160953882000
+16095388205
Full Address
29 Emmons Drive Suite B-10 Princeton, NJ 085400
CIK Number
812,7960
Place of Incorporation
Delaware
Delaware
0
Investors
Third Security
Third Security
0
‌
OpusPoint Partners
Rosland Capital
Rosland Capital
Iroquois Capital Group
Iroquois Capital Group
0
DUNS Number
1538807780
IRS Number
411,505,0290
Founded Date
1987
Fax Number
609-452-64670
Total Funding Amount (USD)
6,660,000
Latest Funding Round Date
May 3, 2013
Competitors
Himalaya Therapeutics
Himalaya Therapeutics
Affinivax
Affinivax
Mast Therapeutics
Mast Therapeutics
OSEL, INC.
OSEL, INC.
0
Cortexyme
Cortexyme
Stock Symbol
SNGX0
Exchange
Nasdaq
Nasdaq
‌
OTC Bulletin Board
Glassdoor ID
8663
Board of Directors
Gregg A. Lapointe
Gregg A. Lapointe
0
‌
Diane Parks
0
‌
Christopher J. Schaber
0
‌
Jerome B. Zeldis
0
CFO
‌
Jonathan Guarino
0
Latest Funding Type
Seed
Seed
NAICS Code
325,4120
CAGE Code
44FA70
Patents Assigned (Count)
11
Wellfound ID
soligenix
Country
United States
United States
0
Headquarters
Princeton, New Jersey
Princeton, New Jersey
0

Other attributes

Company Operating Status
Active
Contact Page URL
soligenix.com/about/contact/
Previous Name
DOR BIOPHARMA INC0
IMMUNOTHERAPEUTICS INC0
ENDOREX CORP0
SIC Code
2,8340
Ticker Symbol
SNGX0
Wikidata ID
Q30283670

Soligenix, Inc. is a biotechnology company that focuses on the development and commercialization of products for treating rare diseases and addressing unmet medical needs.

Soligenix works on improving the lives of patients globally. Its leaders have many years of experience in the biopharmaceutical industry and expertise in developing rare disease therapies.

Soligenix specializes in developing orphan and unmet medical need indications that include preclinical, manufacturing, regulatory and clinical expertise. Soligenix is building SGX301 as a photo-dynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma, SGX942, a novel innate defense regulator technology for the treatment of oral mucositis and SGX203, a proprietary formulations of oral beclomethasone 17, 21-dipropionate (BDP) for the prevention and treatment of gastrointestinal disorders that are characterized by severe inflammation including pediatric Crohn’s disease.

Soligenix offers public health solutions business segment that includes active development programs for RiVax®, its ricin toxin vaccine candidate, SGX943.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Soligenix

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.